Andrew Hendifar, MD, MPH
Enriched profileMedical Director, Pancreatic Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center · Cedars-Sinai Medical Center
Andrew Hendifar is Medical Director, Pancreatic Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center at Cedars-Sinai Medical Center. OpenAlex indexes 462 publications with 14,236 citations (h-index 53); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Andrew Hendifar, MD, MPH, is Medical Director, Pancreatic Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center. The public record shows 462 publications with 14,236 citations (h-index 53), centered on Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Neuroendocrine Tumor Research Advances. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 22 companies.
- Most recent indexed publication: 2026 · Cancer epidemiology, biomarkers & prevention
- Top research focus: Pancreatic and Hepatic Oncology Research
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 140.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
Sponsor: Cedars-Sinai Medical Center
- Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Sponsor: Cantex Pharmaceuticals
Industry payments
Updated 27 Aug 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202517 payments$15,836openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20258 payments$15,371openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20253 payments$11,275openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
60.5%Antidiarrheal microorganisms35.5%Creon83%Zenpep17%Part D<11 patientsSerotonin-3 Receptor Antagonist9.5%Ondansetron Hcl100%Part D≥35 patientsNervous system
11.4%Phenothiazine8.9%Prochlorperazine Maleate100%Part D≥33 patientsSSRI2.5%Trazodone Hcl100%Part D<11 patientsHormonal (systemic)
9.1%Somatostatin Analog6.6%Octreotide Acetate61%Somatuline Depot39%Part D<11 patientsl-Thyroxine2.5%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
182 congress contributions (2005–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 3182: Profiling of B7-H3 CAR T cells generated from patients with pancreatic ductal adenocarcinoma
AACR Annual Meeting
AACR2025Co-author - A supervised prehabilitation program for patients with pancreatic cancer.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Circulating Tumor Cells as the Liquid Biopsy Foray into Noninvasive Colorectal Cancer Screening.
Cancer epidemiology, biomarkers & prevention
Article2026 - Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.
Cancer research communications
Clinical Trial2025 - Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/andrew-hendifar-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Andrew-Hendifar
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/drhendifar
Mentions by others
where others cite or feature them- Instagram
instagram.com/reel/DOW_iZkkZ03
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile: Physician at Cedars Sinai Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →everydayhealth.care ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →yelp.com ↗
- Board Certified: Hematology
Internal Medicine, and Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗ - Residency
Los Angeles County + USC Medical Center; Hematology/Oncology Fellowship, University of Southern California (served as Chief Fellow)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uclaoliveview.org ↗
Editorial & leadership roles
journal and society appointments- Medical Director
Pancreatic Cancer Program, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗ - Lead
Gastrointestinal Disease Research Group, Cedars-Sinai
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Director
Hematology/Oncology Fellowship Program, Cedars-Sinai
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchers.cedars-sinai.edu ↗
Awards & honors
honors on the public record- Dr. Cynthia Mathis Physician Recognition Award (2025)
presented by BLOOM (Black Leaders Overtly Officiating Movement)
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pancan.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- Director
Hematology and Oncology Fellowship Program, Cedars-Sinai
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchers.cedars-sinai.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Text Q&A interview
CancerNetwork, on RAF-altered pancreatic cancer targeted therapy outcomes
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗ - Guest
"Oncology Brothers" video podcast, episode on pancreatic cancer treatment algorithm (with Shubham Pant)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center